<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299325</url>
  </required_header>
  <id_info>
    <org_study_id>PM_C_0172</org_study_id>
    <secondary_id>2005-002568-27</secondary_id>
    <nct_id>NCT00299325</nct_id>
  </id_info>
  <brief_title>VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt</brief_title>
  <acronym>VICTORIA</acronym>
  <official_title>A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To assess the effect of rimonabant on visceral fat area over a period of 12 months when&#xD;
      prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To assess the effect of rimonabant over a period of 12 months on:&#xD;
&#xD;
             -  Liver fat content using CT scan (Computed Tomography scan)&#xD;
&#xD;
             -  Anthropometric measures (weight, waist circumference, body composition using Dual&#xD;
                Energy X-ray Absorptiometry (DEXA))&#xD;
&#xD;
             -  Lipid, lipoprotein profile&#xD;
&#xD;
             -  Glycemia, insulinemia and HbA1c&#xD;
&#xD;
             -  Adipokines, inflammatory and hemostatic markers&#xD;
&#xD;
        -  To evaluate the percentage of patients with metabolic syndrome at 12 months&#xD;
&#xD;
        -  To evaluate the safety and tolerability of rimonabant in these patients&#xD;
&#xD;
      In four selected US sites the effect of rimonabant at 12 months will be also assessed on:&#xD;
&#xD;
        -  Basal lipolysis and insulin suppressed lipolysis (euglycemic hyperinsulinemic clamp).&#xD;
&#xD;
        -  Resting metabolic rate and substrate oxidation at rest using indirect calorimetry.&#xD;
&#xD;
        -  Adipose tissue histology and expression of genes involved in glucose and lipid&#xD;
           metabolism (superficial adipose tissue biopsy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration per patient will be approximately 15 months including a 12-month&#xD;
      double-blind treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change in visceral fat area assessed by CT scan</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in visceral fat area assessed by CT scan</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver fat content measured using CT scan</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometric measures</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in specific lipid parameters</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose control parameters</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adipokines, inflammatory and hemostatic markers</measure>
    <time_frame>From baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of patients with a metabolic syndrome</measure>
    <time_frame>At 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rimonabant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimonabant 20 mg once daily with mild hypocaloric diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Rimonabant) once daily with mild hypocaloric diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Rimonabant</arm_group_label>
    <other_name>SR141716</other_name>
    <other_name>Acomplia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rimonabant)</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mild hypocaloric diet</intervention_name>
    <description>Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rimonabant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Waist circumference &gt; 102 cm in men and &gt; 88 cm in women&#xD;
&#xD;
          -  Two other components of the metabolic syndrome (NCEP/ATPIII definition) among the&#xD;
             following :&#xD;
&#xD;
               -  Triglyceridemia ≥ 150 mg/dl (or 1.69 mmol/L)&#xD;
&#xD;
               -  HDL cholesterol &lt; 50 mg/dL (or 1.29 mmol/L) in women or &lt; 40 mg/dL (or 1.04&#xD;
                  mmol/L) in men&#xD;
&#xD;
               -  Blood pressure ≥ 130/85 mmHg (systolic blood pressure ≥ 130 mmHg and/or diastolic&#xD;
                  blood pressure ≥ 85 mmHg) or Treatment with antihypertensive agent(s) for this&#xD;
                  condition&#xD;
&#xD;
               -  Fasting blood glucose &gt; 110 mg/dl (or 6.1 mmol/L)&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Positive pregnancy test, pregnant or breast-feeding women, or women planning to become&#xD;
             pregnant or breastfeed&#xD;
&#xD;
          -  Absence of medically approved contraceptive methods for female of childbearing&#xD;
             potential&#xD;
&#xD;
          -  History of very low-calorie diet (≤ 800 kcal/day) within 3 months prior to screening&#xD;
             visit&#xD;
&#xD;
          -  History of surgical procedures for weight loss (eg, stomach stapling, bypass).&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the&#xD;
             investigator.&#xD;
&#xD;
          -  Weight change &gt; 5 kg within 3 months prior to screening visit&#xD;
&#xD;
          -  Obese patients (BMI&gt; 40 kg/m²)&#xD;
&#xD;
          -  Established type 1 or 2 diabetes (treated or untreated): at least 2 measures of&#xD;
             fasting blood glucose ≥ 126 mg/dl&#xD;
&#xD;
          -  Severe renal dysfunction (creatinine clearance &lt; 30 ml/min) or nephrotic syndrome&#xD;
&#xD;
          -  Chronic hepatitis or clinically significant hepatic disease&#xD;
&#xD;
          -  Positive test for hepatitis B or C&#xD;
&#xD;
          -  Marijuana or hashish users&#xD;
&#xD;
          -  Significant haematology abnormalities (haemoglobin &lt; 100 g/L and/or neutrophils &lt; 1.5&#xD;
             G/L and/or platelets &lt; 100 G/L).&#xD;
&#xD;
          -  Presence or history of cancer within the past 5 years with the exception of adequately&#xD;
             treated basal cell skin cancer or in situ uterine cervical cancer&#xD;
&#xD;
          -  Presence or history of severe depression that can be defined as depression which&#xD;
             necessitated the patient to be hospitalised, or patient with 2 or more recurrent&#xD;
             episodes of depression or an history of suicide attempt&#xD;
&#xD;
          -  Presence or history of bulimia or anorexia nervosa (DSM-IV (Diagnostic and Statistical&#xD;
             Manual of Mental Disorders) criteria) or binge eating disorders&#xD;
&#xD;
          -  Presence of any other condition (eg geographical, social…) current or anticipated that&#xD;
             the Investigator feels that would restrict or limit the subject's participation for&#xD;
             the duration of the studyRelated to previous or concomitant drugs that could interfere&#xD;
             with the evaluation of study drug effects&#xD;
&#xD;
          -  Administration of any investigational treatment (drug or device) within 30 days prior&#xD;
             to screening&#xD;
&#xD;
          -  Previous participation in a rimonabant study&#xD;
&#xD;
          -  Administration of any of the following within 3 months prior to screening visit:&#xD;
&#xD;
               -  anti obesity drugs (eg, sibutramine, orlistat)&#xD;
&#xD;
               -  other drugs for weight reduction (phentermine, amphetamines)&#xD;
&#xD;
               -  herbal preparations for weight reduction&#xD;
&#xD;
               -  thyroid preparations or thyroxin treatment (except in patients on replacement&#xD;
                  therapy on a stable dose)&#xD;
&#xD;
          -  Patient treated within the last 3 months with nicotinic acid, fibrates, bile acid&#xD;
             sequestrants or ezetimibe (patients treated with statins can be included if the dose&#xD;
             received is stable since at least 3 months and should not be modified during the whole&#xD;
             study period).&#xD;
&#xD;
          -  Patient treated with antidiabetic drug(s).&#xD;
&#xD;
          -  Prolonged use (more than one week) within the last 3 months of systemic&#xD;
             corticosteroids, neuroleptics, or antidepressants (including bupropion).&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hoersholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Triay J, Mundi M, Klein S, Toledo FG, Smith SR, Abu-Lebdeh H, Jensen M. Does rimonabant independently affect free fatty acid and glucose metabolism? J Clin Endocrinol Metab. 2012 Mar;97(3):819-27. doi: 10.1210/jc.2011-2486. Epub 2011 Dec 14.</citation>
    <PMID>22170727</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <disposition_first_submitted>April 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 20, 2016</disposition_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

